These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33657522)

  • 1. Impurity profiling of dapsone using gradient HPLC method.
    Leistner A; Holzgrabe U
    J Pharm Biomed Anal; 2021 May; 198():113982. PubMed ID: 33657522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of RP UPLC-TOF/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities.
    Jadhav SB; Kumar CK; Bandichhor R; Bhosale PN
    J Pharm Biomed Anal; 2016 Jan; 118():370-379. PubMed ID: 26600119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Separation and identification of impurities from intermediates of istradefylline].
    Wang Y; Lü X; Xu H; Meng Z; Li J; Xu Z; Xue M
    Se Pu; 2021 Apr; 39(4):430-436. PubMed ID: 34227764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation pathways and impurity profiling of the anticancer drug apalutamide by HPLC and LC-MS/MS and separation of impurities using Design of Experiments.
    Lakka NS; Kuppan C; Vadagam N; Reddamoni SY; Muthusamy C
    Biomed Chromatogr; 2023 Feb; 37(2):e5549. PubMed ID: 36409057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization, HPLC method development and impurity identification for 3,4,3-LI(1,2-HOPO), a potent actinide chelator for radionuclide decorporation.
    Liu M; Wang J; Wu X; Wang E; Abergel RJ; Shuh DK; Raymond KN; Liu P
    J Pharm Biomed Anal; 2015 Jan; 102():443-9. PubMed ID: 25459944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity.
    Siva Kumar R; Sravan Kumar KV; Kondareddy L; Yogeshwara KR; Manish G; Jeenet J; Nitesh K
    J Chromatogr Sci; 2018 May; 56(5):383-395. PubMed ID: 29474520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Structural Elucidation of New Process Impurity in Testosterone.
    Gupte V; Luthra U; Desai N
    J Chromatogr Sci; 2018 May; 56(5):403-408. PubMed ID: 29554236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyphenated liquid chromatography - diode array detection - charged aerosol detection - high resolution - multistage mass spectrometry with online hydrogen/deuterium exchange: One stop solution for pharmaceutical impurity profiling.
    Thakkar H; Jain S; Kumar S; Bhalekar VS; Gangakhedkar S; Shah RP
    J Chromatogr A; 2023 Jan; 1689():463725. PubMed ID: 36586282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of unknown impurities in Coenzyme Q
    Deng Y; Chen X; Wang L; Peng X; Lin M
    J Pharm Biomed Anal; 2019 Oct; 175():112771. PubMed ID: 31330281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of impurity peaks in the HPLC chromatogram by LC-MS and two-dimensional chromatographic correlation spectroscopy].
    Chen ZZ; Zhang DS; Wang N; Feng F; Hu CQ
    Yao Xue Xue Bao; 2012 Apr; 47(4):492-7. PubMed ID: 22799032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
    Prajapati KJ; Kothari CS
    Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product.
    Luo Z; Deng Z; Liu Y; Wang G; Yang W; Hou C; Tang M; Yang R; Zhou H
    Talanta; 2015 Jul; 139():67-74. PubMed ID: 25882410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of mobile phase gradient supercritical fluid chromatography for impurity profiling of pharmaceutical compounds.
    Alexander AJ; Hooker TF; Tomasella FP
    J Pharm Biomed Anal; 2012 Nov; 70():77-86. PubMed ID: 22687460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Identification of the impurity in auramine O by high performance liquid chromatography-ion trap-time of flight mass spectrometry and preparation of the auramine O reference standard by preparative high performance liquid chromatography].
    Che F; Lu Y; Xi X; Lan T; Wei Y
    Se Pu; 2019 Mar; 37(3):299-304. PubMed ID: 30900859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
    Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
    J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).
    Liu M; Wang J; Liu P
    J Pharm Biomed Anal; 2016 Nov; 131():429-435. PubMed ID: 27661436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.